All News

Make every month a celebration of wellbeing at the pharmacy by leveraging disease awareness initiatives.

In a recent conversation with Drug Topics on Over the Counter, Mark Garofoli discusses why men avoid seeking medical help for pain, as well as potential solutions.

The COVID-19 pandemic led to increased pharmacist burnout and workforce shortages. The impact is still being felt today.

Researchers tested various text-to-image generation platforms to better understand issues of representation within artificial intelligence.

A study found that CT scans of visceral fat had the highest predictive performance of incident diabetes.

From expanding vaccination coverage to battling with PBMs, the community pharmacist has the ability to promote change like never before.

See what’s trending in pharmacy with a preview of the Total Pharmacy August issue.

A study found that test products purchased from illegal online pharmacy operations had lower purity levels and significantly more semaglutide content than what was advertised on the label.

Finerenone (Kerendia) was previously approved in 2021 to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease associated with type 2 diabetes.

As clinical research continues, investigators are learning more about how GLP-1 drugs modify cardiovascular risks.

Lifestyle changes—including eating fruits, vegetables, and whole grains—can help patients, especially those with diabetes or hypertension, improve outcomes.

In case you missed it, this week we had news about CVS in the spotlight of PBM reform, landmark FDA approvals in synovial sarcoma, liraglutide for dementia, and more.

Sharing concrete steps and suggestions can help ease the way for patients looking to transition to a more healthful lifestyle.

Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.

Check out this recap of articles published on our sister sites during the past week.

GLP-1 therapies are being evaluated to treat cardiovascular and kidney diseases in individuals with overweight or obesity.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.

Some patients may have difficulty managing the gastrointestinal adverse effects associated with GLP-1 therapies.

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Check out important updated from the FDA for the week of July 29.

Researchers aimed to discover whether pharmacist-led delivery of oral anticoagulation therapy can lead to an increase in stroke risk reduction for patients with actionable atrial fibrillation.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Afami-cel is the first new treatment for synovial sarcoma in more than 10 years, ending a long-standing therapeutic gap.

Liraglutide slowed the loss of volume in critical brain regions and cognitive decline in patients with mild Alzheimer's dementia.

Pharmacists should be knowledgeable about the symptoms of chemical peel irritation to effectively advise patients.

In 3 Phase 3 trials, elinzanetant reduced the frequency and severity of moderate to severe vasomotor symptoms, and improved sleep disturbances.

Researchers aimed to address the association of all-cause dementia risk and 3 separate chronicities of anxiety.